title: Role of protease and protease inhibitors in cancer pathogenesis and treatment.
abstract: Cancer is the second cause of death in 2015, and it has been estimated to surpass heart diseases as the leading cause of death in the next few years. Several mechanisms are involved in cancer pathogenesis. Studies have indicated that proteases are also implicated in tumor growth and progression which is highly dependent on nutrient and oxygen supply. On the other hand, protease inhibitors could be considered as a potent strategy in cancer therapy. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. In this review, we focus on the role of different types of proteases and protease inhibitors in cancer pathogenesis.
authors.affiliation: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Department of Medical Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Lorestan, Iran. Electronic address: a-eatemadi@razi.tums.ac.ir.
authors.forename: Ali
authors.initials: A
authors.lastname: Eatemadi
authors.affiliation: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran; Tehran University of Medical Sciences International Campus (TUMS-IC), Tehran, Iran.
authors.forename: Hammed T
authors.initials: HT
authors.lastname: Aiyelabegan
authors.affiliation: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Babak
authors.initials: B
authors.lastname: Negahdari
authors.affiliation: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Mazlomi
authors.affiliation: Department of Medical Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Lorestan, Iran; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Hadis
authors.initials: H
authors.lastname: Daraee
authors.affiliation: Department of Medical Biotechnology, School of Medicine, Lorestan University of Medical Sciences, Lorestan, Iran; Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Nasim
authors.initials: N
authors.lastname: Daraee
authors.affiliation: University of Ilam, Ilam, Iran.
authors.forename: Razieh
authors.initials: R
authors.lastname: Eatemadi
authors.affiliation: Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: sadroddiny@sina.tums.ac.ir.
authors.forename: Esmaeil
authors.initials: E
authors.lastname: Sadroddiny
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D063646:Carcinogenesis / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D010447:Peptide Hydrolases / Q000378:metabolism*; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017433:Protein Structure, Secondary; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011480:Protease Inhibitors; D010447:Peptide Hydrolases
keywords: Protease; Protease inhibitor; cancer